Research
Hormonal
GLP-1 receptor agonists (GLP1-RA) and SGLT2 inhibitors (SGLT2-i) are effective interventions for obesity-related cardiometabolic complications by reducing body weight and addressing pathophysiological derangements.
If lifestyle changes are insufficient, discuss GLP-1 RAs or SGLT2 inhibitors with your doctor. These medications are now recognized as essential tools for managing obesity and its heart/kidney risks, not just for diabetes.
StrongSupportsHIGH confidence
Among the newer and available drugs, both the glucagon-like peptide-1 receptor (GLP1-RA) and the sodium-glucose cotransporter-2 inhibitors (SGLT2-i) can improve metabolic and CV risk factors by reducing body weight and acting on associated pathophysiological derangements.
Why this rating
Cited as 'innovative' and 'changing management' with strong clinical backing implied by their widespread adoption for T2DM and obesity.
Source
Adipocentric origin of the common cardiometabolic complications of obesity in the young up to the very old: pathophysiology and new therapeutic opportunities
Riccardo Sarzani et al. · Frontiers in Medicine · 2024
narrative_reviewCited 13×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →